Lista de obras -

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

artículo científico publicado en 2000

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

artículo científico publicado en 2014

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

artículo científico publicado en 2020

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

artículo científico publicado en 2014

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

artículo científico publicado en 2010

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study

artículo científico publicado en 2017

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

artículo científico publicado en 2005

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

artículo científico publicado en 2003

Antiphospholipid Syndrome: Definition and Treatment ⬇️

artículo científico publicado el 1 de abril de 2003

Antiphospholipid antibodies and pregnancy.

artículo científico publicado en 2003

Antiphospholipid antibodies and thrombosis: strength of association

artículo científico publicado en 2003

Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests

artículo científico publicado en 2005

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

artículo científico publicado en 2016

Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?

artículo científico publicado en 2007

Chronic myeloproliferative disorders

artículo científico publicado en 2003

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

artículo científico publicado en 2007

Comments on pre-fibrotic myelofibrosis and how should it be managed

scientific article published on 07 March 2019

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

artículo científico publicado en 2007

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

artículo científico publicado en 2014

Efficacy and safety of low-dose aspirin in polycythemia vera

artículo científico publicado en 2004

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

artículo científico publicado en 2005

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment

artículo científico publicado en 2012

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

artículo científico publicado en 2017

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

artículo científico publicado en 2009

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

scientific article published on 07 January 2021

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

artículo científico publicado en 2009

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

artículo científico publicado en 2005

Indications for lowering platelet numbers in essential thrombocythemia

artículo científico publicado en 2003

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

artículo científico publicado en 2010

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

artículo científico publicado en 2019

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

artículo científico publicado en 2012

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

artículo científico publicado en 2005

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

artículo científico publicado en 2007

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

artículo científico publicado en 2014

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

artículo científico publicado en 2002

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

artículo científico publicado en 2018

Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia

artículo científico publicado en 2002

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

artículo científico publicado en 2015

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management

artículo científico publicado en 2018

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

artículo científico publicado en 2004

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

artículo científico publicado en 2017

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

scientific article published on 01 November 2020

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

artículo científico publicado en 2016

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

artículo científico publicado en 2007

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

artículo científico publicado en 2005

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

artículo científico publicado en 2011

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

artículo científico publicado en 2019

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

artículo científico publicado en 2019

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

artículo científico publicado en 2011

The European LeukemiaNet: achievements and perspectives

artículo científico publicado en 2010

The haematocrit and platelet target in polycythemia vera

artículo científico publicado en 2007

The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?

artículo científico publicado en 2004

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

artículo científico publicado en 2013

Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients

artículo científico publicado en 2005

Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia

artículo científico publicado en 2003

What is the standard treatment in essential thrombocythemia

artículo científico publicado en 2002

When and how to treat essential thrombocythemia

artículo científico publicado en 2005

Lista de obras de

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Antiphospholipid Syndrome: Definition and Treatment ⬇️

Antiphospholipid antibodies and pregnancy.

Antiphospholipid antibodies and thrombosis: strength of association

Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?

Chronic myeloproliferative disorders

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

Comments on pre-fibrotic myelofibrosis and how should it be managed

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Efficacy and safety of low-dose aspirin in polycythemia vera

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

Indications for lowering platelet numbers in essential thrombocythemia

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

The European LeukemiaNet: achievements and perspectives

The haematocrit and platelet target in polycythemia vera

The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients

Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia

What is the standard treatment in essential thrombocythemia

When and how to treat essential thrombocythemia